Cidara Therapeutics Announces Workforce Reduction and Clinical Trial Plans

Details

announced a reduction in its workforce of 20 employees, approximately 30% of its total workforce, as part of its strategic focus on the clinical development of its influenza product candidate, CD388. The reduction is expected to be completed by November 1, 2024, with estimated charges of approximately $1.2 million for severance and employee benefits, primarily in Q4 2024. Additionally, on September 12, 2024, the company announced plans to initiate a Phase 2b clinical trial for CD388 in the third quarter of 2024, with no current plans for clinical trials of other product candidates.

Items reported

About Cidara Therapeutics Inc.

Cidara Therapeutics Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. Its primary function involves addressing unmet medical needs in the treatment of serious infectious diseases and immune-based conditions. Emphasizing innovation, Cidara Therapeutics is known for its pioneering Cloudbreak platform, which integrates potent drug conjugates designed to address life-threatening bacterial, viral, and fungal infections. The asset prominently impacts the biotechnology and pharmaceutical sectors, endeavoring to transform standard infection treatments with its advanced therapeutic solutions. Cidara's pipeline includes the development of new antifungal agents like rezafungin, aimed at treating invasive fungal infections that significantly affect immunocompromised patients. With its strategic focus, Cidara Therapeutics plays a critical role in the emerging markets of antimicrobial resistance and immunotherapy. Positioned within the healthcare industry, Cidara's contributions hold significant potential to alter existing therapies and specialize in meeting complex medical challenges, reinforcing the broader landscape of pharmaceutical advancements and patient care strategies.